Associated tags: Organic, Biotechnology, Health, Cell, Genetics, Clinical Trials, Great Ormond Street Hospital, CFO, CDMO, GMP, Patient, Therapy, OXB, Vaccine, Finance, Doctor of Philosophy, LSE, Gene, Oxford Biomedica, Science
Locations: NEW YORK, NORTH AMERICA, UNITED STATES, IRELAND, UNITED KINGDOM, EUROPE, UK, CAR
Complimentary attendance at this event is available for credentialed investors and members of the media only.
Key Points:
- Complimentary attendance at this event is available for credentialed investors and members of the media only.
- Investors should contact Laura Stringham at [email protected] and interested media should contact Stephen Majors at [email protected] .
- ViroCell Biologics is an innovation-driven Contract Development and Manufacturing Organisation (“CDMO”) focused exclusively on the design and GMP manufacture of viral vectors for clinical trials.
- Focused initially on manufacturing lentivirus and gamma-retrovirus vectors, ViroCell enables clients to start clinical trials on a scalable platform, delivering value by reducing costs, time and regulatory risk.
Retrieved on:
Wednesday, November 1, 2023
Manufacturing,
Finance,
Pharmaceutical,
General Health,
Professional Services,
Philanthropy,
Hospitals,
Genetics,
Clinical Trials,
Other Manufacturing,
Foundation,
Biotechnology,
Science,
Other Science,
Research,
Health,
Child,
ICH,
AAV,
Health care,
Therapy,
Rare,
Rare disease,
United Arab Emirates,
Organic,
UCL,
CGT,
Multimedia,
Lentivirus,
Great Ormond Street Hospital,
Growth,
GOSH,
Cell,
ZCR,
MHRA,
Association de médiation sociale v Union locale des syndicats CGT,
Partnership,
Zayed Center for Coordination and Follow-Up,
Zayed bin Sultan Al Nahyan,
GMP,
Patient,
MIA,
Vaccine,
Hospital This shortage in clinical trial vector supply is believed to be slowing the progress of bringing novel medicines to patients.
Key Points:
- This shortage in clinical trial vector supply is believed to be slowing the progress of bringing novel medicines to patients.
- With ViroCell now able to leverage GOSH's state-of-the-art manufacturing facility, the Company is poised to relieve the strain on clinical research caused by the vector shortage and expand the supply of precisely engineered viral vectors for clinical trials.
- The MHRA is widely considered a gold-standard regulatory authority, with its rigorous requirement for facility inspection and licencing for advanced therapy manufacturing for clinical trials.
- Therefore, in addition to accelerating CGT clinical trials in the UK, this approval could also help accelerate the start of new clinical trials worldwide, as ViroCell ramps up the manufacturing of vectors for global export.
Retrieved on:
Wednesday, October 4, 2023
Health,
Genetics,
Stem Cells,
Pharmaceutical,
Clinical Trials,
Molecular oncology,
Duke University,
LSE,
Business development,
University,
Oxford Biomedica,
Therapy,
Gene,
Biotechnology,
Business,
TMO,
Thermo Fisher Scientific,
CMDO,
CTLT,
Organic,
Doctor of Philosophy,
OXB,
Colon,
Regenerative medicine,
Harvard Medical School,
CDMO,
Patient,
Mesa,
Cell,
CFO,
Growth,
Commercial Operating System,
Ecosystem,
Newcastle University,
Team,
NYSE,
Catapult,
National Technical University of Athens,
Non-executive director,
Pharmaceutical industry,
Fine chemical,
Science,
Biology Focused on driving growth in the US and Europe, respectively, Traci and Makis bring a wealth of business development expertise to ViroCell from roles across CMDO businesses focused on cell and gene therapy.
Key Points:
- Focused on driving growth in the US and Europe, respectively, Traci and Makis bring a wealth of business development expertise to ViroCell from roles across CMDO businesses focused on cell and gene therapy.
- Joining ViroCell to accelerate business growth across Europe, Makis brings over 25 years of biopharmaceutical experience marked by contributions to the development of innovative biotechnology products and successful businesses.
- Most recently, he was Director of Business Development at Catalent Cell and Gene Therapy (“Catalent”, NYSE: CTLT), a CDMO specialising in advanced therapeutics.
- Before this, Makis worked at the UK’s Cell and Gene Therapy Catapult as a Business Development Manager.
Professional Services,
Health,
Genetics,
Finance,
Clinical Trials,
Biotechnology,
GMP,
LSE,
Risk,
Oxford Biomedica,
Gene,
Great Ormond Street Hospital for Children NHS Foundation Trust,
B2B,
Avery Dennison,
Organic,
Doctor of Philosophy,
OXB,
CDMO,
Cell,
HR,
H.B. Fuller,
CFO,
Growth,
Great Ormond Street Hospital,
Operational excellence,
Non-executive director,
Pharmaceutical industry,
Management,
Vaccine ViroCell Biologics (“ViroCell” or the “Company”), a specialist Contract Development and Manufacturing Organisation (“CDMO”) in cell and gene therapy clinical trials, announces the appointment of Brian Collins as Chief Financial Officer (“CFO”).
Key Points:
- ViroCell Biologics (“ViroCell” or the “Company”), a specialist Contract Development and Manufacturing Organisation (“CDMO”) in cell and gene therapy clinical trials, announces the appointment of Brian Collins as Chief Financial Officer (“CFO”).
- John W. Hadden II, CEO at ViroCell, commented, “I am delighted to welcome Brian to the ViroCell team.
- Prior to the CGT Catapult, Brian was the CFO of Coveris Packaging and before that held numerous financial and operational roles of increasing seniority at companies, including MSX International, HB Fuller and Avery Dennison.
- Throughout his 30-year career in finance, Brian has built finance operations, led acquisitions, and secured company financings.
